'BIT225 is inactive against HIV-2, which lacks Vpu, and displays a cell culture EC50 (concentration that gives half-maximal response) of ∼2 μM against HIV-1, with improved efficacy against macrophage-tropic compared with T-cell-tropic strains. As with HMA, the binding mode and inhibitory mechanism of this small molecule are unknown, and resistant polymorphisms in Vpu have not been reported.'
Can't be good in a commercial sense!
Major Article - BIT225, in combination with 3-drug antiretroviral therapy, page-219
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
